Literature DB >> 9257773

In vitro evaluation of voriconazole against some clinically important fungi.

M R McGinnis1, L Pasarell, D A Sutton, A W Fothergill, C R Cooper, M G Rinaldi.   

Abstract

Voriconazole was compared to amphotericin B, fluconazole, and itraconazole by using an in vitro macrobroth dilution test based upon current National Committee for Clinical Laboratory Standards tentative standards against the dimorphic fungi and several opportunistic molds and yeasts. In all instances, the voriconazole MICs were lower than those of fluconazole. In most instances, the MICs were lower than the recorded MICs of amphotericin B and itraconazole.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9257773      PMCID： PMC164017     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  6 in total

Review 1.  Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards.

Authors:  J H Rex; M A Pfaller; J N Galgiani; M S Bartlett; A Espinel-Ingroff; M A Ghannoum; M Lancaster; F C Odds; M G Rinaldi; T J Walsh; A L Barry
Journal:  Clin Infect Dis       Date:  1997-02       Impact factor: 9.079

2.  Efficacy of UK-109496, a new azole antifungal agent, in an experimental model of invasive aspergillosis.

Authors:  D George; P Miniter; V T Andriole
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

3.  Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis.

Authors:  M Murphy; E M Bernard; T Ishimaru; D Armstrong
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

4.  Comparison of voriconazole (UK-109,496) and itraconazole in prevention and treatment of Aspergillus fumigatus endocarditis in guinea pigs.

Authors:  M V Martin; J Yates; C A Hitchcock
Journal:  Antimicrob Agents Chemother       Date:  1997-01       Impact factor: 5.191

5.  In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens.

Authors:  S A Radford; E M Johnson; D W Warnock
Journal:  Antimicrob Agents Chemother       Date:  1997-04       Impact factor: 5.191

6.  In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species.

Authors:  A L Barry; S D Brown
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191
  6 in total
  31 in total

Review 1.  Fungal resistance.

Authors:  H Bernhardt; K Zimmermann; M Knoke
Journal:  Infection       Date:  1999       Impact factor: 3.553

2.  Arthroconidia in lung tissue: an unusual histopathological finding in pulmonary coccidioidomycosis.

Authors:  Thea Brennan-Krohn; Edward Yoon; Michiya Nishino; James E Kirby; Stefan Riedel
Journal:  Hum Pathol       Date:  2017-08-01       Impact factor: 3.466

3.  Peptide immunization as an adjuvant to chemotherapy in mice challenged intratracheally with virulent yeast cells of Paracoccidioides brasiliensis.

Authors:  A F Marques; M B da Silva; M A P Juliano; L R Travassos; C P Taborda
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

4.  In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa.

Authors:  M A Pfaller; J Zhang; S A Messer; M E Brandt; R A Hajjeh; C J Jessup; M Tumberland; E K Mbidde; M A Ghannoum
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

Review 5.  Clinical, cellular, and molecular factors that contribute to antifungal drug resistance.

Authors:  T C White; K A Marr; R A Bowden
Journal:  Clin Microbiol Rev       Date:  1998-04       Impact factor: 26.132

6.  Comparison of high-performance liquid chromatographic and microbiological methods for determination of voriconazole levels in plasma.

Authors:  S Perea; G J Pennick; A Modak; A W Fothergill; D A Sutton; D J Sheehan; M G Rinaldi
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

7.  Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens.

Authors:  L Purkins; N Wood; P Ghahramani; K Greenhalgh; M J Allen; D Kleinermans
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

Review 8.  Dimorphic fungal osteoarticular infections.

Authors:  B Rammaert; M N Gamaletsou; V Zeller; C Elie; R Prinapori; S J Taj-Aldeen; E Roilides; D P Kontoyiannis; B Brause; N V Sipsas; T J Walsh; O Lortholary
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-06-18       Impact factor: 3.267

9.  In vitro efficacy and fungicidal activity of voriconazole against Aspergillus and Fusarium species.

Authors:  C J Clancy; M H Nguyen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-08       Impact factor: 3.267

10.  In vitro comparison of activities of terbinafine and itraconazole against Paracoccidioides brasiliensis.

Authors:  R C Hahn; C J F Fontes; R D Batista; J S Hamdan
Journal:  J Clin Microbiol       Date:  2002-08       Impact factor: 5.948
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.